At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KLTO Klotho Neurosciences, Inc.
Post-Mkt 01-09 16:39:57 EST
0.3381
-0.0043
-1.26%
盘后0.3500
+0.0119+3.52%
16:36 EST
High0.3558Low0.3381Vol318.64K
Open0.3499D1 Closing0.3424Amplitude5.17%
Mkt Cap24.52MTradable Cap19.20MTotal Shares72.54M
T/O111.15KT/O Rate0.56%Tradable Shares56.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Klotho Neuroscience Sells $15M in Series C Preferred Stock to Sigma9 Capital
Reuters  ·  2025-12-09
Klotho Neuroscience Sells $15M in Series C Preferred Stock to Sigma9 Capital
Klotho Neurosciences Inc - Files Prospectus for Offer and Resale by Selling Stockholders of up to 34.9 Mln Shares of Common Stock
THOMSON REUTERS  ·  2025-12-06
Klotho Neurosciences Inc - Files Prospectus for Offer and Resale by Selling Stockholders of up to 34.9 Mln Shares of Common Stock
Klotho Neurosciences Q3 EPS $(0.05) Up From $(0.18) YoY
Benzinga  ·  2025-11-14
Klotho Neurosciences Q3 EPS $(0.05) Up From $(0.18) YoY
Klotho and Turn allow Letter of Intent to expire
TIPRANKS  ·  2025-10-08
Klotho and Turn allow Letter of Intent to expire
BRIEF-Klotho Neurosciences Announces Expiration Of Letter Of Intent
Reuters  ·  2025-10-08
BRIEF-Klotho Neurosciences Announces Expiration Of Letter Of Intent
Klotho Neurosciences Inc: Loi With Turn Biotechnologies Allowed to Expire by Parties
THOMSON REUTERS  ·  2025-10-08
Klotho Neurosciences Inc: Loi With Turn Biotechnologies Allowed to Expire by Parties
Klotho Neurosciences Announces Expiration of Letter of Intent
THOMSON REUTERS  ·  2025-10-08
Klotho Neurosciences Announces Expiration of Letter of Intent
Klotho Neurosciences Inc - to Buy $300 Mln Signed Out-Licensing and Co-Development Partnership With South Korean Pharma Cos
THOMSON REUTERS  ·  2025-09-30
Klotho Neurosciences Inc - to Buy $300 Mln Signed Out-Licensing and Co-Development Partnership With South Korean Pharma Cos
Klotho Neurosciences Inc - Plans to Rebrand After Deal Completion
THOMSON REUTERS  ·  2025-09-30
Klotho Neurosciences Inc - Plans to Rebrand After Deal Completion
Klotho Neurosciences Inc - to Buy Turn's Era Platform and Eturna Rna Delivery System
THOMSON REUTERS  ·  2025-09-30
Klotho Neurosciences Inc - to Buy Turn's Era Platform and Eturna Rna Delivery System
Press Release: Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
Dow Jones  ·  2025-09-30
Press Release: Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
Klotho Neuroscience Extends Private Placement Agreement, Caps Share Offering at 6.76 Million
Reuters  ·  2025-09-26
Klotho Neuroscience Extends Private Placement Agreement, Caps Share Offering at 6.76 Million
Klotho Neuroscience Inc. Receives Nasdaq Delisting Warning for Failure to Maintain $1 Minimum Bid Price
Reuters  ·  2025-09-26
Klotho Neuroscience Inc. Receives Nasdaq Delisting Warning for Failure to Maintain $1 Minimum Bid Price
Klotho Neurosciences CEO to Attend Inaugural Klotho Conference & Scientific Seminar in Irvine, California
Reuters  ·  2025-09-08
Klotho Neurosciences CEO to Attend Inaugural Klotho Conference & Scientific Seminar in Irvine, California
Klotho Neurosciences Q2 EPS $(0.12) Down From $(0.03) YoY
Benzinga  ·  2025-08-18
Klotho Neurosciences Q2 EPS $(0.12) Down From $(0.03) YoY
Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development
Reuters  ·  2025-08-18
Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
THOMSON REUTERS  ·  2025-08-18
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
Klotho Neuroscience Inc. Delays Q2 2025 Financial Report Due to Incomplete Financial Statements
Reuters  ·  2025-08-14
Klotho Neuroscience Inc. Delays Q2 2025 Financial Report Due to Incomplete Financial Statements
Klotho Neuroscience Unveils Breakthrough in Gene Therapy Manufacturing with AAVnerGene Collaboration
Reuters  ·  2025-08-12
Klotho Neuroscience Unveils Breakthrough in Gene Therapy Manufacturing with AAVnerGene Collaboration
Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health
Reuters  ·  2025-07-26
Klotho Neurosciences Inc. Expands Beyond Neurology to Enhance Longevity and Health

Introduction

Company Name.
Klotho Neurosciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Issue price:
--